# KRAS Engages AGO2 to Enhance Cellular Transformation

Graphical Abstract

Authors

Sunita Shankar,
Sethuramasundaram Pitchiaya,
Rohit Malik, ..., Nils G. Walter,
Chandan Kumar-Sinha,
Arul M. Chinnaiyan

Correspondence

arul@umich.edu

In Brief

Shankar et al. show that RAS interacts with AGO2, a key component of the RNA-silencing machinery. Interaction of oncogenic KRAS with AGO2 in the endoplasmic reticulum inhibits AGO2 function, elevates mutant KRAS protein levels, and enhances cellular transformation. AGO2 is required for maximal KRAS-mediated oncogenesis.

Highlights

- RAS interacts with AGO2 in the membrane component of the endoplasmic reticulum

- The N terminus of AGO2 directly binds the Switch II domain of RAS

- Oncogenic KRAS association inhibits AGO2-mediated microRNA duplex unwinding

- AGO2 interaction elevates oncogenic KRAS levels to enhance cellular transformation

CrossMark

CellPress

KRAS Engages AGO2 to Enhance Cellular Transformation

Sunita Shankar,[1,2] Sethuramasundaram Pitchiaya,[1,2,3] Rohit Malik,[1,2] Vishal Kothari,[1,2] Yasuyuki Hosono,[1,2]
Anastasia K. Yocum,[1,2] Harika Gundlapalli,[1,2] Yasmine White,[4] Ari Firestone,[4] Xuhong Cao,[1,5]
Saravana M. Dhanasekaran,[1,2] Jeanne A. Stuckey,[6,7] Gideon Bollag,[8] Kevin Shannon,[4] Nils G. Walter,[3]
Chandan Kumar-Sinha,[1,2] and Arul M. Chinnaiyan[1,2,5,9,10,*]
[1]Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109, USA
[2]Department of Pathology, University of Michigan, Ann Arbor, MI 48109, USA
[3]Single Molecule Analysis Group, Department of Chemistry, University of Michigan, Ann Arbor, MI 48109, USA
[4]Department of Pediatrics and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco,
CA 94158, USA
[5]Howard Hughes Medical Institute, University of Michigan, Ann Arbor, MI 48109, USA
[6]Life Science Institute, University of Michigan, Ann Arbor, MI 48109, USA
[7]Department of Biological Chemistry, University of Michigan, Ann Arbor, MI 48109, USA
[8]Plexxikon Inc., Berkeley, CA 94710, USA
[9]Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA
[10]Department of Urology, University of Michigan, Ann Arbor, MI 48109, USA
*Correspondence: arul@umich.edu
http://dx.doi.org/10.1016/j.celrep.2016.01.034

SUMMARY

Oncogenic mutations in RAS provide a compelling yet intractable therapeutic target. Using co-immunoprecipitation mass spectrometry, we uncovered an interaction between RAS and Argonaute 2 (AGO2). Endogenously, RAS and AGO2 co-sediment and co-localize in the endoplasmic reticulum. The AGO2 N-terminal domain directly binds the Switch II region of KRAS, agnostic of nucleotide (GDP/GTP) binding. Functionally, AGO2 knockdown attenuates cell proliferation in mutant *KRAS*-dependent cells and *AGO2* overexpression enhances *KRAS*^{G12V}-mediated transformation. Using *AGO2*−/− cells, we demonstrate that the RAS-AGO2 interaction is required for maximal mutant KRAS expression and cellular transformation. Mechanistically, oncogenic KRAS attenuates AGO2-mediated gene silencing. Overall, the functional interaction with AGO2 extends KRAS function beyond its canonical role in signaling.

INTRODUCTION

Approximately one-third of human cancers harbor an oncogenic mutation in *HRAS*, *KRAS*, or *NRAS* (Balmain and Pragnell, 1983; Karnoub and Weinberg, 2008; Pylayeva-Gupta et al., 2011). The tumor types most frequently harboring *RAS* mutations, predominantly in *KRAS*, include pancreatic, lung, and colon carcinoma, among others (COSMIC, 2013; Hand et al., 1984; Karachaliou et al., 2013; Lauchle et al., 2006;

Löhr et al., 2005). *RAS* genes encode a family of small GTPases (Sweet et al., 1984) that transduce extracellular growth signals by cycling between an active GTP-bound state and an inactive GDP-bound state (Karnoub and Weinberg, 2008; Schubbert et al., 2007). Oncogenic Ras proteins exhibit reduced intrinsic GTPase activity and are resistant to negative regulation by GTPase-activating proteins (GAPs) such as p120GAP and neurofibromin (Cichowski and Jacks, 2001). Constitutively elevated levels of Ras-GTP aberrantly activate downstream effector pathways that promote neoplastic transformation (Karnoub and Weinberg, 2008; Shaw and Cantley, 2006; Trahey and McCormick, 1987). Despite extensive characterization of the Ras/GAP molecular switch(es) and downstream signaling axes, therapeutic targeting of RAS-driven cancers remains elusive (Baines et al., 2011; Downward, 2003; Stephen et al., 2014).

The oncogenic activity of RAS-GTP is mediated through canonical effectors including RAF, PI3 kinase (PI3K), and RalGDS (Cox and Der, 2010; Karnoub and Weinberg, 2008), and other effectors have been described in various contexts (Gysin et al., 2011). RAS effectors bind through the conserved Switch I and Switch II domains and drive cellular transformation by activating downstream kinases and GTPase-signaling modules, the best known of which are the RAF/MEK/ERK (mitogen activation protein [MAP] kinase) and the PI3K/Akt signaling cascades. RAS interactors have been identified using conventional approaches of ectopically expressed epitope-tagged *RAS* constructs (Goldfinger et al., 2007; Vasilescu et al., 2004). Here, we employed co-immunoprecipitation followed by mass spectrometry (coIP MS) to analyze the endogenous interactome of RAS in a panel of lung and pancreatic cancer cell lines representing the spectrum of both *KRAS* mutation and dependency status. Surprisingly, the most prominent interacting protein, across all cell lines analyzed,

was EIF2C2, commonly known as Argonaute 2 (AGO2), a key effector of the RNA-silencing pathway. Interestingly, a role for AGO2 in RAS-induced senescence has been described recently (Benhamed et al., 2012; Yang et al., 2014). Also, phosphorylation of AGO2 by MAPK/PI3K pathway activators has been shown to alter its microRNA-related function through different mechanisms (Horman et al., 2013; Rüdel et al., 2011; Shen et al., 2013; Zeng et al., 2008), portending a broader, direct interface between intracellular signaling and RNA-silencing mechanisms (Paroo et al., 2009). Considering the potential functional implications of RAS-AGO2 interaction, here we corroborated and characterized this interaction in detail.

RESULTS

Endogenous RAS and AGO2 Interaction

To analyze RAS-interacting proteins in an endogenous setting, we first used the pan-RAS antibody RAS10 (Cheng et al., 2011), which efficiently immunoprecipitates RAS proteins by binding to the Switch I domain (amino acids [aa] 32–40; Figures S1A–S1C). Co-immunoprecipitation of RAS followed by tandem mass spectrometry (RAS coIP MS) was performed as outlined in Figure S1D using a panel of ten lung and pancreatic cancer cell lines of known *KRAS* mutation status (Table S1), as well as NIH 3T3 cells ectopically overexpressing human *KRAS* wild-type (*KRAS*^{WT}) or mutant (*KRAS*^{G12V}) proteins. Peptide fragments deduced from MS analyses spectral counts revealed robust detection of the bait protein (RAS) in all the 12

cell lines, as expected (Table S2). To minimize individual cell-specific observations in the endogenous system employed, we focused on observations common across different cell lines. Intriguingly, peptides spanning EIF2C2 protein, commonly known as AGO2, the catalytic component of the RNA-induced silencing complex (RISC), were observed in the RAS coIP MS of all cancer cell lines (n = 10) tested, as well as in NIH 3T3 cells expressing *KRAS*^{WT} or *KRAS*^{G12V} (Figure 1A). Remarkably, only the RAS and AGO2 peptides were detected in every cell line tested, with cumulative spectral counts of 576 and 229, respectively. Other interactors detected in five or more of the 12 cell lines are tabulated in Table S2. The significant lack of peptides spanning the RAS effectors like RAF/PI3K in the endogenous mass spectrometric analysis is due to the RAS10 antibody binding the Switch I domain, preventing effector binding (Figure S1C). The lack of other RAS regulators like SOS1 and NF1 that associate with RAS through the Switch II domain may be due to their transient association and plasma-membrane-localized/cell-specific expression. Interestingly, we did not detect peptides spanning AGO2 in our earlier mass-spectrometric-based studies involving ERG, PRC complex protein EED (Brenner et al., 2011; Cao et al., 2014), and at least four other protein pull-down data sets (data not shown), indicating the specificity of AGO2 coIP with RAS. Analyzing the RAS coIP MS data further, we noted peptides mapping uniquely to all three RAS family members, namely KRAS, NRAS, and HRAS, were readily detected across the cell line panel (Figure 1B). In contrast, almost all uniquely mapping peptides to AGO family proteins were specific to AGO2 in all of the 12 cell lines (except for a single unique peptide that mapped to AGO1 in one sample; Figure 1B).

Figure 2. Co-sedimentation and Co-localization of RAS and AGO2 in the Endoplasmic Reticulum

(A) Cell fractionation analysis of H358 cells to show enrichment of distinct proteins in the cytosolic/membrane or organelle/nuclear fractions. GAPDH was used as a cytosolic marker whereas SAM68 and H3 histone were used as nuclear markers.

(B) Sucrose density gradient fractionation of cell lysates from H358 cells followed by immunoblot detection of total RAS, KRAS, AGO1, and AGO2 proteins.

(C) Representative images of immunofluorescence analysis of RAS (red) and AGO2 (green) in H358, MIA PaCa-2, and DLD-1 cells. Yellow spots in merged images indicate perinuclear co-localization of RAS and AGO2. The nucleus was visualized by DAPI staining (blue). Dotted boxes highlight plasma membrane regions predominantly localized by RAS. Manders overlap coefficient in the intracellular regions of the cells is indicated on the right. An overlap coefficient of 0 suggests no co-localization, whereas a value of 1 indicates complete co-localization. The inset shows a magnified 5.3 × 5.3 μm view of the areas marked. Images are pseudocolored maximum intensity projections (across 2.5 μm), obtained from 3D imaging. The scale bar represents 5 μm.

(D) Representative images of immunofluorescence analysis of AGO2 (green), RAS (red), and ER marker, PDI, (blue) in MiaPaca-2 cells. White spots indicate co-localization signals for RAS/AGO2/PDI in each panel. Pairwise Manders overlap coefficients are shown on the right. The inset shows a magnified 6.7 × 6.7 μm view of the areas marked. The scale bar represents 5 μm.

See also Figure S2.

The putative endogenous interaction between RAS and AGO2 was corroborated by reciprocal IPs using two different antibodies for each, in two different lung cancer cell lines, H358 and H460, harboring distinct *KRAS* mutations (Figure 1C). Further, consistent with the coIP MS analyses (Figure 1A), the RAS-AGO2 interaction was readily detected by coIP followed by immunoblot analysis in two cell lines with wild-type *KRAS* and representative lung and pancreatic cancer cells harboring various activating mutations of *KRAS* (Figure 1D). The observed RAS-AGO2 interaction was maintained even under highly stringent conditions of 1 M NaCl (Figure S1E). The RAS-AGO2 coIP was maintained in the presence of RNase, suggesting that the interaction is independent of AGO2 interaction with RNA (Figures S1F and S1G). To demonstrate further specificity of this interaction, we overexpressed FLAG-tagged *AGO2* construct in HEK293 cells and detected RAS in FLAG immunoprecipitates (Figure S1H). We also performed the coIP analysis in genetically engineered "*RAS*less" mouse embryonic fibroblast cells (Drosten et al., 2010) and failed to detect this interaction upon ablation of KRAS expression (Figure S1I), further establishing the specificity of the RAS-AGO2 interaction.

Co-localization of RAS and AGO2 in the Membrane Component of Endoplasmic Reticulum

RAS proteins are known to localize to the plasma membrane and membranes of various intracellular organelles like the endoplasmic reticulum (ER), Golgi, and mitochondria with distinct signaling outputs (Bivona et al., 2006; Prior and Hancock, 2012). AGO2 is known to assemble in the ER (Kim et al., 2014; Stalder et al., 2013), cytoplasm (Höck et al., 2007), and nucleus (Dudley and Goldstein, 2003; Gagnon et al., 2014). Consistent with this observation, fractionation of H358 cells revealed that RAS was restricted mainly to the membrane (plasma membrane and endomembrane) fraction along with AGO2, which was also detected in the cytoplasmic and nuclear extracts (Figure 2A). Sedimentation analyses using sucrose density gradient showed that total RAS and mutant KRAS predominantly co-sedimented with AGO2 in smaller-molecular-weight fractions (Complex I; Figure 2B) as defined by a previous study (Höck et al., 2007).

Next, to assess co-localization of endogenous RAS and AGO2, we performed indirect immunofluorescence using RAS10 and AGO211A9 (Rüdel et al., 2008) antibodies in

A

RAS binding

Construct	RAS binding
1-859	+
N terminal	+
50-859	+
140-859	−
227-859	−
MID	−
PIWI	−
AGO2K98A	+
AGO2K112A	−
AGO2K114A	−

B

C

Figure 3. The N-Terminal Domain of AGO2 Interacts with RAS

(A) Schematic summary of FLAG-tagged *AGO2* deletion and mutant constructs used for RAS coIP analyses.

(B) Expression of FLAG-tagged N-terminal, PAZ, or PIWI domains of *AGO2* in HEK293 cells (left), followed by RAS IP (right). Immunoblot analysis shows that deletion of (1–226 aa) N-terminal domain in AGO2 abrogates RAS interaction.

(C) Expression of indicated *AGO2* N-terminal point mutant constructs within the wedge domain (50–139 aa) in HEK293 cells, followed by RAS coIP analysis.

See also Figure S3.

efficient analysis indicative of signal overlap between the two proteins was determined to be 0.53, 0.65, and 0.60 in H358, MIA PaCa-2, and DLD-1 cells, respectively (where 1 is considered complete overlap and 0 is considered no overlap). These findings suggest significant co-localization of RAS and AGO2 predominantly in the intracellular perinuclear regions of cells (Figure 2C).

Given that cytoplasmic RAS is restricted to the endomembrane bound organelles, we performed a three-color immunofluorescence staining for RAS and AGO2 along with specific protein markers of different organelles in MIA PaCa-2 cells. Whereas we observed a significant signal overlap between RAS, AGO2, and ER marker (PDI; Figures 2D and S2B), Manders coefficient values were minimal for Golgi (RCAS1), endo-somal (Rab5/7/11), or mitochondrial (COX4) markers (Figures S2B and S2C). This suggests that endogenous RAS and AGO2 are predominantly found in the ER (Manders coefficient for both RAS in ER and AGO2 in ER was 0.62 each), where they co-localize. Hence, along with the cell fractionation ana-lyses, these immunofluorescence data suggest that a subset of RAS proteins

co-localizes with AGO2 in the endomembranous components of the ER.

AGO2 Binds RAS through Its N-Terminal Wedge Domain

To identify specific region(s) in AGO2 involved in the interaction with RAS, we employed a panel of FLAG-epitope-tagged AGO2 expression constructs (summarized in the schematic in Figure 3A). RAS coIP analysis of the FLAG-tagged AGO2 dele-tion constructs showed that the N-terminal domain of AGO2

different cells. To ascertain the specificity of RAS10 Ab, antigenic peptides were used for competition prior to imm-unofluorescence analysis (Figure S2A); in addition, AGO211A9 has been demonstrated to be a highly specific, validated monoclonal antibody for immunofluorescence detection of AGO2 (Rüdel et al., 2008). In H358, MIA PaCa-2, and DLD-1 cells (Figure 2C), RAS staining was visible both at the plasma membrane and intracellular regions, whereas only cytoplasmic staining was detected for AGO2. Manders co-

Figure 4. The Switch II Domain of RAS Interacts with AGO2

(A) Schematic summary of the antibodies and recombinant proteins used for RAS-AGO2 coIP analysis to identify residues in RAS, critical for AGO2 interaction.
(B) RAS coIP using antibodies that bind Switch I domain (RAS10 Ab) or Switch II domain (Y13-259 Ab), followed by immunoblot analysis for RAS and AGO2.
(C–E) Characterization of direct RAS-AGO2 interaction, in vitro. (C) Immunoblot analysis following in vitro coIP of recombinant KRASG12V (top) and KRASWT (bottom) in the presence of varying concentrations of recombinant AGO2 is shown. (D) In vitro coIP analysis of KRAS-AGO2 interaction using a panel of KRAS mutant proteins spanning amino acid residues 62–65 in the Switch II domain is shown. (E) Immunoblot analysis following His-AGO2 pull-down assay using Ni-NTA beads upon incubation with different KRAS mutant proteins is shown.
See also Figure S4.

was necessary (Figure 3B) and sufficient (Figure S3A) for RAS binding. Further analysis of a panel of deletion constructs spanning the N-terminal domain suggested that the region spanning 50–139 aa was critical for RAS binding (Figure S3B). Interestingly, this aa stretch was recently shown to be part of the "wedging" domain, important for microRNA duplex unwinding prior to RISC assembly (Kwak and Tomari, 2012). To further define AGO2 residues critical for interaction with RAS, we focused on the 50–139 aa stretch that is uniquely present in AGO2 (and not in AGO1, 3, or 4) based on the fact that, among the Argonaute family proteins, AGO2 was almost singularly represented in the RAS coIP MS data. ClustalW alignment of all human Argonaute proteins (AGO1–4) identified ten residues unique to AGO2 in this region (Figure S3C). Alanine substitution of each of the ten residues was followed by RAS coIP analysis, and aa K112 and E114 of AGO2 were found to be critical for a direct association with RAS (Figure 3C).

Y64 Residue within the Switch II Domain of KRAS Is Critical for Direct AGO2 Binding

In a parallel analysis aiming to define the residues in RAS critical for AGO2 association, we first employed two RAS antibodies that bind exclusively either to the Switch I (RAS10 mAb) or the Switch II (Y13-259) domains (summarized in Figure 4A). Whereas both antibodies efficiently immunoprecipitated RAS in H358 cell lysates, AGO2 was present only in IPs with Switch-I-specific RAS10 Ab and not in Switch-II-specific Y13-259 Ab (Figure 4B), suggesting that the Switch II domain in RAS is critical for AGO2 interaction. Next, we hypothesized that, if the RAS-AGO2 interaction is restricted through contacts with the Switch II domain, we may be able to detect AGO2 in RAS-GTP complexed with RAF, on RAS-binding domain (RBD) agarose beads. As predicted, we were able to detect AGO2 on RAS-GTP bound to RBD-agarose in H358 (*KRAS*^{G12C}) cells (Figure S4A), further supporting that AGO2 binds to the Switch II domain of GTP-bound KRAS.

Figure 5. *AGO2* Is Essential for Mutant *KRAS*-Dependent Cell Proliferation

(A) Immunoblot analysis of AGO2 and KRAS after knockdown or overexpression of *AGO2*.

(B and C) Growth curves (B) and colony formation assays (C) of mutant *KRAS*-dependent H358 lung cancer cells, following either knockdown of *KRAS/AGO2* using shRNA or *AGO2* overexpression. Error bars are based on SEM. *(p < 0.05) and **(p < 0.005) denote significant differences in growth at the indicated times compared to either scrambled or vector control. Data were obtained from three independent experiments.

(D) Pathscan intracellular signaling arrays probed with lysates from H358 cells following *AGO2* knockdown.

(E) Growth curves (left) and colony formation assays (right) of mutant *KRAS*-independent H460 lung cancer cells, following knockdown of *KRAS/AGO2*. Data obtained from three independent experiments are shown. Inset shows immunoblot analysis of AGO2 and KRAS upon *AGO2* knockdown.

(F) Intracellular signaling array probed with lysates from H460 following *AGO2* knockdown.

(legend continued on next page)

Next, we sought to determine the specific residues in the Switch II region of KRAS involved in its interaction with AGO2, using in vitro coIP assays. Purified recombinant KRASG12V or KRASWT proteins were incubated with varying concentrations of AGO2 protein followed by RAS immunoprecipitation. We observed a concentration-dependent, direct interaction between recombinant AGO2 and both the wild-type and mutant KRAS proteins (Figure 4C). Further, in vitro coIP of recombinant AGO2 protein with the panel of Switch II mutant KRAS proteins showed that altering the Y64 residue (but not the neighboring aa) significantly reduced KRAS binding to AGO2 (Figure 4D). To further substantiate this observation, and to obviate potential technical concerns inherent in antibody-based coIP, we carried out an antibody-independent pull-down assay using recombinant His-tagged AGO2 protein bound to Ni-NTA beads. Consistent with the in vitro coIP analyses, the His-tagged AGO2 pull-down assay also showed specific dependency of AGO2-RAS binding on the Y64 residue (Figure 4E).

To assess whether GDP/GTP loading of KRAS may influence the AGO2 interaction in vitro, we carried out in vitro coIP analyses using KRASWT and KRASG12V proteins loaded with GDP/GTPγS and as seen in Figure S4B. Our results showed that AGO2 binding was agnostic to nucleotide loading status of KRAS. Similarly, both the KRASWT and KRASG12V proteins were observed to bind to His-tagged AGO2, independent of the nucleotide loading on KRAS (Figure S4C). To validate the efficiency and specificity of nucleotide loading onto KRAS proteins, we performed RAF-RBD pull-down assays and observed the expected differential between GDP- and GTP-bound KRAS with respect to RAF-RBD binding (Figure S4D). Thus, these data define the aa in RAS (Y64) and AGO2 (K112/E114) as critical for the RAS-AGO2 interaction.

Reduced RISC Activity Elevates Oncogenic KRAS Levels, Making AGO2 Essential for Mutant KRAS-Dependent Cell Proliferation

Next, we set out to analyze functional implications of the RAS-AGO2 interaction, particularly in the context of KRAS-driven transformation. To this end, we first carried out knockdown of AGO2 in H358 lung cancer cells that harbor a homozygous KRAS mutation and are known to be KRAS dependent (Symonds et al., 2011). Whereas the microRNA let-7/AGO2 axis is

reported to negatively regulate wild-type RAS levels (Diederichs and Haber, 2007; Johnson et al., 2005), we observed a remarkable reduction in mutant KRAS protein levels in H358 cells with AGO2 knockdown (Figure 5A, left panel). Conversely, overexpression of AGO2 in the same cells led to elevated levels of KRAS, implying a positive regulation of mutant KRAS levels by AGO2 (Figure 5A, right panel). Consistent with these observations, knockdowns of AGO2 and/or KRAS in H358 cells (using two independent shRNAs; Figures S5A and S5B) showed reduced rates of cell proliferation whereas AGO2 overexpression resulted in increased cell proliferation (Figure 5B). Furthermore, AGO2 knockdown reduced the ability of H358 cells to form colonies in colony formation assays (Figure 5C) and resulted in a marked reduction in levels of known mediators of KRAS signaling, including p-Akt, p-mTOR, and p-RPS6 based on our analysis with Pathscan intracellular signaling array (Cell Signaling Technology; Figures 5D, S5C, and S5D). Interestingly, similar AGO2 depletion experiments (using the same shRNAs described above) in KRAS-independent H460 lung cancer cells, which also harbors a mutant KRAS, did not affect cell proliferation, colony formation (Figure 5E), or intracellular signaling (Figures 5F and S5E). Phenotypic effects upon AGO2 knockdown in the context of KRAS dependency were also observed in pancreatic cancer cell lines, where knockdown of either KRAS or AGO2 dramatically reduced cell proliferation in mutant KRAS-dependent MIA PaCa-2 cells, but not in mutant KRAS-independent PANC-1 cells (Figures 5G, S5A, and S5B). Further, AGO2-depleted MIA PaCa-2 cells failed to establish xenografts in SCID mice (Figure 5H), with a concomitant reduction in KRAS protein levels (Figure 5H, inset). These data suggest that KRAS-dependent cancer cells manifest a coincident dependence on AGO2 to maintain oncogenic KRAS protein levels and support a functional role for AGO2 in potentiating the oncogenic activities of mutant KRAS.

To directly address the consequence of mutant KRAS binding at the N-terminal of AGO2, critical for microRNA duplex unwinding (Kwak and Tomari, 2012; Wang et al., 2009), we performed let-7 unwinding assays in isogenic colorectal cancer cells, DLD-1, harboring heterozygous KRAS[G13D] (MUT/WT) alleles or wild-type KRAS (−/WT). Dually labeled double-stranded let-7a (Figure 5I, schematic) was injected and assessed for the extent of single strand formation. Quantitation of the

(G) Growth curves of pancreatic cancer cells, MIA PaCa-2 (mutant KRAS dependent; left), and PANC-1 (mutant KRAS independent; right) following knockdown of KRAS or AGO2, as indicated. *(p < 0.05) and **(p < 0.005) denote significant differences in growth at the indicated times compared to scrambled control. Data were obtained from three independent experiments.

(H) In vivo growth of Mia PaCa-2 cells transiently treated with either scrambled shRNA or shRNA targeting AGO2 prior to injecting in nude mice. For each group (n = 8), one million cells were injected and average tumor volume (in mm^3) was plotted on y axis and days after injection on the x axis. Right shows immunoblot analysis of AGO2 and RAS following AGO2 knockdown in Mia PaCa-2 cells. Indicated p value was calculated using two-sided Student's t test for the two groups.

(I) (Top) Schematic of the labeled let-7 microRNA used in the intracellular strand unwinding assays. Straight lines and double dots represent Watson-Crick and Wobble pairs, respectively. The thermodynamically unstable end (highlighted in yellow) promotes asymmetric loading of the guide strand. (Bottom left) Representative images of the guide strand (green) and passenger strand (red) of let-7 microRNA, 30 min post-intracellular injections in DLD-1 isogenic lines, expressing wild-type KRAS (−/WT) or KRAS[G12C] (MUT/WT) are shown. Numbers represent the guide:passenger strand ratio. Ratio of 1:1 indicates attenuation of let-7 dsRNA unwinding whereas a higher guide:passenger strand ratio indicates efficient unwinding and functional RISC. The scale bar represents 10 μm. (Bottom right) Native acrylamide gel electrophoresis of let-7 unwinding assay and immunoblot analysis of DLD-1 isogenic cell line extracts is shown. M1 and M2 represent double- (ds) and single-stranded (ss) markers, respectively.

(J) Box plot representing the guide:passenger strand ratio in the indicated cell lines with varying KRAS mutation status. Whiskers represent minimum and maximum values, and line represents median of the data set (n ≥ 2; no. cells ≥ 13; ***p < 0.0005). Red asterisk indicates cells expressing mutant KRAS. See also Figure S5.

guide-to-passenger strand ratio was estimated 30 min after injection, where a 1:1 ratio was considered as no unwinding whereas higher ratios indicate active unwinding. As seen in Figure 5I (left), the formation of single-stranded (ss) RNA molecules from double-stranded (ds) *let-7* substrates, a key step in the formation of active RISC, was attenuated in DLD-1 MUT/WT cells (ratio = 1.3). Duplex unwinding was restored in isogenic cells lacking mutant KRAS (−/WT; ratio = 5.7). Biochemical assays using cellular lysates followed by gel electrophoresis also showed reduced *let-7* unwinding in DLD-1 MUT/WT cells (Figure 5I, right), even though the RAS-AGO2 interaction was detected in both DLD-1 isogenic cells (Figure S5F). Additionally, the *let-7* unwinding assay was performed in mouse embryonic fibroblasts lacking AGO2 (MEF*AGO2*−/−) and *MEFAGO2*−/− reconstituted with AGO2 (MEF*AGO2*−/− + *AGO2*; Broderick et al., 2011) to demonstrate that the microRNA unwinding assay is AGO2 dependent (Figures S5G and S5H). Further, to circumvent any artificial effects of gene knockout models, we subjected multiple cancer cells, naturally harboring different KRAS alleles, to the same *let-7* unwinding assay. As seen in Figures 5J and S5I, only oncogenic KRAS-expressing cells showed reduced *let-7* unwinding, indicative of diminished AGO2 function in cells harboring mutations in *KRAS*.

Mutant KRAS-AGO2 Interaction Promotes Cellular Transformation

To address the mechanistic underpinnings of the phenotypic effects associated with the mutant KRAS-AGO2 interaction, we employed the classic NIH 3T3 experimental model system to ectopically express human *KRAS^{WT}* or *KRAS^{G12V}* (Qiu et al., 1995; Shih et al., 1981), with or without *AGO2*, and carried out transient foci formation assays. As expected, no foci were observed in cells transfected with *KRAS^{WT}*, as well as in cells with *KRAS^{WT}* ± *AGO2*. However, NIH 3T3 cells transfected with *KRAS^{G12V}* generated characteristic foci of transformed cells. Remarkably, co-transfection of *KRAS^{G12V}* with AGO2 enhanced the number of foci by approximately 5-fold, compared to the vector control (Figure 6A). In contrast, *AGO2* overexpression did not enhance *BRAF^{V600E}*-driven focus formation (Figure S6A), suggesting that *AGO2* specifically potentiates RAS-mediated oncogenesis, most likely as a result of its direct interaction with RAS. In vivo experiments using a mouse xenograft model also showed a significant increase in tumor growth with cells expressing *KRAS^{G12V}*+*AGO2* compared to *KRAS^{G12V}*+vector control (Figure S6B). As expected, in these experiments, cells expressing either *KRAS^{WT}* or *AGO2* alone did not develop tumors. Consistent with *AGO2* overexpression in H358 cells (Figure 5A), immunoblot analysis of NIH 3T3 cells overexpressing *AGO2* showed an increase in KRAS protein levels (Figure 6B).

To understand the effects of AGO2 on the RAS-signaling pathways, we analyzed protein lysates from NIH 3T3 cells stably expressing *KRAS^{G12V}*+vector or *KRAS^{G12V}*+*AGO2* using the Pathscan intracellular signaling arrays. Cells expressing *KRAS^{G12V}*+*AGO2* showed a marked increase in the levels of p-Akt, p-mTOR, p-RPS6, and p-BAD, but not phospho-ERK (Figures 6C, right panel, S5C, and S5D), suggesting that the increased levels of oncogenic KRASG12V protein signals largely through PI3K activation.

Exploiting the NIH 3T3 overexpression model to probe the reciprocal effects of mutant KRAS on AGO2 function, we profiled microRNAs from foci obtained from *KRAS^{G12V}*+vector and *KRAS^{G12V}*+*AGO2* using high-throughput sequencing. Whereas AGO2 overexpression is known to elevate levels of mature microRNAs (Diederichs and Haber, 2007), we observed a marked reduction in microRNA levels (214/781) in *KRAS^{G12V}*+*AGO2*-expressing foci, including most of the *let-7* family members (Figure S6E). Interestingly, a small proportion (27/781) of microRNAs was elevated and included known "oncomiRs" *miR-221* and *miR-222*. microRNA qPCR analysis of NIH 3T3 cells expressing *AGO2* alone or *KRAS^{WT}*/*KRAS^{G12V}* ± *AGO2* also showed reduced *let-7* levels only in the *KRAS^{G12V}* +*AGO2*-expressing cells (Figure S6F), suggesting an inhibition of AGO2 function in oncogenic KRAS-expressing cells.

To further investigate a requirement for an AGO2 interaction in *KRAS^{G12V}*-driven transformation, we first performed in vitro RAS coIP assays using mutant KRASG12D and the double mutant KRASG12DY64G, which has previously been shown to have limited oncogenic potential (Shieh et al., 2013). Whereas KRASG12D binds AGO2, KRASG12DY64G failed to bind AGO2 (Figure S6G). Transfecting a retroviral vector encoding *KRAS^{G12VY64G}* double mutant into NIH 3T3 cells failed to generate foci (Figure 6D). As an important corollary to our hypothesis that mutant KRAS-AGO2 interaction leads to elevated mutant KRAS protein levels, the *KRAS^{G12VY64G}* stably expressing cells also showed much-lower levels of KRAS protein than *KRAS^{G12V}*-expressing cells (Figure 6E, top panel). An independent construct encoding *KRAS^{G12VY64G}* showed similar results despite high levels of KRAS transcript expression (Figures S6H–S6J). Curiously, RBD assays suggest that expressed *KRAS^{G12VY64G}* was GTP loaded and activated phospho-Akt and phospho-ERK similar to *KRAS^{G12V}*, suggesting that, although *KRAS^{G12VY64G}* levels are low, it is GTP loaded and likely signaling at the membrane. Yet, despite expressing activated RAS, NIH 3T3 stable cells expressing *KRAS^{G12VY64G}* failed to show the characteristic morphology of *KRAS^{G12V}* cells (Figure 6E, bottom panel). In vivo, these cells also failed to establish tumors in the xenograft mouse model (Figure 6F), supporting a critical role for Switch II region (Y64) in KRAS-driven transformation, including its association with AGO2.

Whereas NIH 3T3 cells stably expressing *KRAS^{G12V}* showed reduced *let-7* levels, *KRAS^{G12VY64G}*-expressing cells, which do not allow for the mutant KRAS-AGO2 interaction, showed no change in *let-7* expression, providing evidence for a direct role of mutant KRAS in the modulation of microRNA levels in this model (Figure S6K). Cognate analysis of the levels of *let-7* target transcripts (Lee and Dutta, 2007) showed an almost log-fold change in the mRNA levels of *HMGA1* and *HMGA2* only in *KRAS^{G12V}*-expressing cells (Figure S6L). Together, our data using the *KRAS^{G12VY64G}* mutant and *let-7* levels as readout of AGO2 function broadly support the conclusion that mutant KRAS, through its direct association, inhibits AGO2 activity.

To more directly explore the potential effect of *KRAS^{G12V}* on functional messenger ribonucleoprotein particles (mRNPs), we exploited a recently described method for intracellular single-molecule, high-resolution localization and counting (iSHiRLoC)

Figure 6. Mutant KRAS-AGO2 Interaction Promotes Transformation

(A) Representative images of foci formation assays using NIH 3T3 cells co-transfected with KRAS^{WT} or $KRAS^{G12V}$ and $AGO2$ (left panel). Quantitation of foci from two technical replicate experiments (right panel) is shown. Foci assays were performed at least three times with similar results. p value was calculated using two-sided Student's t test between the two groups.

(B) Immunoblot analysis shows increased levels of oncogenic KRAS levels in the presence of AGO2.

(C) Intracellular signaling arrays probed with lysates from NIH 3T3 cells stably expressing vector, $AGO2$, or $KRAS^{G12V} \pm AGO2$. The colored circles mark duplicate spots corresponding to p-AKT (S473), p-RPS6 (S235/236), and p-mTOR (S2448).

(D) Representative images of foci formation assays using NIH 3T3 cells co-transfected with $KRAS^{G12V}$ or $KRAS^{G12VY64G}$. Quantitation of foci from two independent experiments (right) is shown. Indicated p value was calculated using two-sided Student's t test.

(E) KRAS immunoprecipitation (using sc-521 pAb) followed by immunoblot analysis (RAS10 Ab) showing low levels of oncogenic KRAS protein expression in NIH 3T3 cells stably expressing $KRAS^{G12VY64G}$. RAS-GTP levels were assessed using RBD agarose beads. Signaling through phospho-Akt and phospho-ERK activation was performed after serum starvation by immunoblot analysis. Lower panel shows morphology of indicated stable lines grown in 10% serum upon crystal violet staining.

(F) In vivo growth of NIH 3T3 cells stably overexpressing $KRAS^{G12V}$ and $KRAS^{G12VY64G}$ in nude mice. For each group (n = 8), 500,000 cells were injected and average tumor volume (in mm^3) was plotted on y axis and days after injection on the x axis.

(G) (Left) Representative 3.14 × 3.14 μm^2 regions from NIH 3T3 (top left), NIH 3T3-KRAS^{WT} (top right), NIH 3T3-KRAS^{G12V} (bottom left), and NIH 3T3-KRAS^{G12V,Y64G} cells (bottom right) that were imaged 4 hr (h) after microinjection of let-7-a1-Cy5. Individual particle tracks (colored) and their net displacements (white arrow) over a 5-s period (time; color bar) are shown. Shorter displacement vectors indicate let-7 assembly in larger mRNP complexes with less mobility, whereas longer white arrows indicate let-7 assembly in smaller mRNP complexes with high mobility. (Right) Graphical representation of ratio of "slow"-moving complexes (particles with diffusion coefficients <0.06 μm^2/s) and "fast"-moving complexes (particles with diffusion coefficients >0.06 μm^2/s), normalized to the first hour time point, are plotted as a function of time.

See also Figure S6.

of microRNAs (Pitchiaya et al., 2012, 2013). Diffusion coefficients of microinjected fluorophore-labeled *let-7a* molecules suggest that, in NIH 3T3 cells expressing *KRAS^WT^*, *let-7a* assembles into both ''fast'' (low molecular weight) and ''slow'' (high molecular weight) mRNA-protein complexes (mRNPs; Figures 6G and S6M). By contrast, in cells expressing *KRAS^G12V^*, *let-7a* manifested predominantly in fast-moving complexes, suggesting that *let-7a* is unable to accumulate in larger mRNPs (known to be functional RISC; Pitchiaya et al., 2012, 2013) in an oncogenic *KRAS* setting. Importantly, in cells expressing *KRAS^G12VY64G^*, *let-7a* accumulates in both fast and slow mRNPs, further implicating that a direct interaction between mutant KRAS and AGO2 is essential to prevent functional RISC assembly. Thus, the NIH 3T3 overexpression model suggests that, through its interaction with AGO2, mutant KRAS modulates levels of mature microRNAs likely due to its ability to inhibit an early step of RISC assembly.

AGO2 Interaction Is Required to Maximize Oncogenic Potential of Mutant KRAS

To further underscore the role of AGO2 in *KRAS^G12V^*-driven oncogenesis, we generated NIH 3T3 cells with *AGO2* knockout (NIH 3T3 *AGO2*−/−) using the CRISPR/Cas9 methodology (Ran et al., 2013; Figure S7A). Validation of *AGO2* knockout in NIH 3T3 *AGO2*−/− cells was performed at the DNA, RNA, and protein levels (Figures S7B–S7D). Sucrose density sedimentation analysis of NIH 3T3 *AGO2*−/− showed that, in contrast to NIH 3T3 parental cells, RAS is restricted largely to the first four fractions of the gradient with minimal overlap with AGO1 complexes, indicating that RAS associates with higher-molecular-weight fractions through its interaction with AGO2 (Figure 7A). NIH 3T3 *AGO2*−/− cells had lower levels of *let-7* family microRNAs (Figure S7E), consistent with previous studies demonstrating that a loss of AGO2 results in reduction of absolute levels of all microRNAs (Diederichs and Haber, 2007). In NIH 3T3 *AGO2*−/− cells, the reduction of *let-7* family microRNA levels also resulted in a concomitant increase in *let-7* target (*HMGA1/HMGA2*) transcript levels (Figure S7F).

Despite reduced levels of microRNAs, *KRAS^G12V^* expression in the NIH 3T3 *AGO2*−/− cells showed a markedly reduced ability to generate foci compared to parental NIH 3T3 (Figures 7B and S7G). Partial rescue of the ability to establish foci in these cells was achieved by overexpression of *AGO2* or *AGO2^K98A^* (which permits RAS interaction), but not the *AGO2^K112A^* mutant (which does not bind RAS; Figure 3C). These observations also support the notion that a direct association of oncogenic KRAS and AGO2 is required for mutant KRAS-driven transformation. In addition, NIH 3T3 *AGO2*−/− cells stably expressing *KRAS^G12V^* did not display the characteristic morphology of NIH 3T3 *KRAS^G12V^* cells (Figure 7C, top panel). In vivo experiments in a mouse xenograft model also showed significantly decreased tumor growth, with NIH 3T3 AGO2−/− cells expressing *KRAS^G12V^* compared to parental NIH 3T3 cells expressing *KRAS^G12V^*, further demonstrating a requirement for AGO2 in KRAS-driven transformation (Figure 7C, lower panel). At the protein level, NIH 3T3 *AGO2*−/− cells stably expressing *KRAS^G12V^* showed reduced expression of mutant KRAS compared to that of NIH 3T3 cells stably expressing *KRAS^G12V^* (Figure 7D). Reduced acti-

vation of phospho-Akt signaling by mutant KRAS and a slight increase in phospho-ERK signaling in NIH 3T3 AGO2−/− cells suggests that AGO2 plays an essential role in modulating the signaling output of mutant KRAS.

Taken together, we have established AGO2 as a critical regulator of RAS-GTP in cells, and our study posits an essential role for the KRAS-AGO2 interaction in oncogenic KRAS-driven cellular transformation.

DISCUSSION

RAS, one of the first proto-oncogenes identified (DeFeo et al., 1981), has emerged as one of the genes with most-frequent recurrent mutations in a broad spectrum of human cancers. In recent years, there is a renewed interest in targeting RAS to alter its status from an undruggable to druggable candidate (Burns et al., 2014; Ostrem et al., 2013; Spiegel et al., 2014; Stephen et al., 2014; Sun et al., 2012). In this context, discovery of novel endogenous interactors of RAS could potentially advance our understanding of RAS biology and provide additional therapeutic avenues.

Here, we identify the interaction of RAS with AGO2, a key mediator of RNA-based gene silencing (Czech and Hannon, 2011; Peters and Meister, 2007; Wilson and Doudna, 2013). Like guanine nucleotide exchange factors (GEFs), AGO2 binds RAS-GTP and RAS-GDP and likely interacts functionally with both wild-type and oncogenic RAS proteins (Jeng et al., 2012; Margarit et al., 2003). Furthermore, AGO2 and RAS co-localize in the ER, known sites for both RAS trafficking and AGO2 RISC activity. The KRAS-AGO2 interaction involves Y64 in the Switch II domain of KRAS and K112-E114 residues in the N-terminal Wedge domain of AGO2 (Figure 7E). Functionally, the mutant KRAS-AGO2 interaction is critical for KRAS-mediated oncogenesis. Mechanistically, mutant KRAS binding attenuates AGO2 N-terminal-dependent microRNA duplex unwinding, critical for functional RISC assembly. Reciprocally, AGO2 modulates mutant-KRAS-mediated signaling output, particularly the AKT-mTOR pathway.

Our study focused on analyzing endogenous interactors of RAS, common across a panel of cancer cells spanning the spectrum of KRAS aberrations. To the best of our knowledge, this is the first study using endogenous RAS as bait for mass spectrometric analyses, as all previous coIP MS analyses used N-terminal epitope-tagged *HRAS*, *MRAS*, or *RRAS* ectopically expressed in NIH 3T3 cells (Goldfinger et al., 2007; Vasilescu et al., 2004). Studies using tagged AGO2 as bait for mass spectrometry have also been reported (MacRae et al., 2008; Meister et al., 2005) and, as a 25-kDa cutoff was employed for analyses, may have missed the detection of the 21 kDa RAS protein. In this study, the pull-down of AGO2 using multiple independent antibodies consistently co-precipitated RAS (Figure 1C), and we found that this interaction is direct, as assessed using purified components (Figure 4). Endogenously, the RAS-AGO2 interaction is readily detected in both cancer and benign cells, independent of *KRAS* mutation status (Figure 1D), portending a fundamental role for this interaction in the cell.

KRAS interacts with AGO2 through the Switch II domain, the Y64 residue being critical for its AGO2 association. The

Figure 7. AGO2 Interaction Is Required for Maximal Oncogenic Potential of Mutant KRAS

(A) Sucrose density gradient fractionation of parental NIH 3T3, NIH 3T3 $KRAS^{G12V}$, and NIH 3T3 $AGO2-/-$ cell lysates followed by immunoblot detection of RAS, AGO1, and AGO2 proteins.

(B) (Left) Representative images of $KRAS^{G12V}$-driven foci in NIH 3T3 and NIH 3T3 $AGO2-/-$ cells upon co-transfection with various $AGO2$ constructs. (Right) Quantitation of foci from two replicate experiments is shown. Error bars show SEM, and asterisks indicate p values less than 0.005 for the indicated conditions compared to vector control.

(C) Upper panel shows crystal violet staining of indicated stable lines grown in 10% serum. (Lower panel) In vivo growth of NIH 3T3 or NIH 3T3 $AGO2-/-$ cells stably expressing $KRAS^{G12V}$ in nude mice is shown. For each group (n = 8), 500,000 cells were injected and average tumor volume (in mm³) was plotted on y axis and days after injection on the x axis. Error bars are SEM. *p < 0.05 and **p < 0.005 at the indicated times.

(D) Immunoblot analysis showing reduced expression of oncogenic KRAS in $KRAS$ $AGO2-/-$ stably expressing $KRAS^{G12V}$ and the extent of phospho-ERK and phospho-AKT activation in these cells.

(E) Schematic representation of the N-terminal domain of AGO2 interacting with the Switch II domain in RAS.

See also Figure S7.

Switch II domain and particularly Y64 was recently demonstrated to be critical in hematopoietic malignancies, where $KRAS^{G12DY64G}$ mutant expressed at lower levels compared to $KRAS^{G12D}$ (Shieh et al., 2013), much like we observed in our NIH 3T3 model, extending a role for the KRAS-AGO2 interaction in models other than lung and pancreas. It should be noted that the Switch II domain in RAS is the site for allosteric regulation through its binding to various regulators and may contribute to the biological effects observed in these studies. Yet, this study provides a first instance where the mutant KRAS Switch II domain (and Y64) has a direct bearing on RISC assembly through its association with AGO2.

The AGO2 N-terminal domain represents the most-distinct region in the highly conserved AGO protein family. A recent report (Kwak and Tomari, 2012) suggests that the region we identified in AGO2 as critical for RAS binding (i.e., the "wedge domain") is important for small RNA duplex unwinding, a prerequisite for RISC assembly. Using isogenic lines, we demonstrate that mutant KRAS, but not wild-type KRAS, interaction with AGO2 attenuates microRNA duplex unwinding function with a direct bearing on AGO2-RISC assembly. Inhibition of RISC assembly by mutant KRAS may be the critical step that likely contributes to global loss of microRNA levels and downstream effects on increased protein translation of target mRNAs, features of

human tumors (Lu et al., 2005). Because we have used mutant KRAS constructs that do not have 3′ UTR regions that can bind microRNAs, it remains unclear how AGO2 elevates mutant KRAS levels (Figures 5A and 6B) to increase its transformation potential.

Recent studies have shown that KRAS, but not HRAS, translation is tightly regulated by rare synonymous codons of the *KRAS* transcript (Lampson et al., 2013; Pershing et al., 2015), suggesting a significant role for KRAS regulation at a level prior to its better-characterized post-translational modifications. An association of mutant KRAS with the RNA machinery through binding to HNRNPA2B1 was also reported (Barceló et al., 2014), supporting a likely interface of RAS with the RNA-processing machinery, including the hub protein AGO2 as observed in our study. The EGFR kinase was also recently shown to phosphorylate AGO2 in response to hypoxia, leading to inhibition of AGO2-mediated microRNA processing (McCarthy, 2013; Shen et al., 2013). Similarly, Akt was shown to phosphorylate AGO2 to inhibit *AGO2*-mediated mRNA endonucleolytic activity (Horman et al., 2013). Interestingly, AGO2 phosphorylation also leads to inhibition of microRNA loading into RISC complexes in the presence of mutant $HRAS^{G12V}$ (Yang et al., 2014). The identification of AGO2 as a critical partner of RAS further provides a direct mechanistic link between RAS oncogenic signaling and RNA silencing. Further illumination of such integral effector mechanisms of RAS may inform novel approaches to therapeutically target this frequently mutated cancer pathway.

EXPERIMENTAL PROCEDURES

Co-immunoprecipitation and Tandem Mass Spectrometric Analysis
Methods used for immunoprecipitation with RAS/control IgG followed by tandem mass spectrometric analysis and database searching are schematically outlined in Figure S1D. Complete data of the peptides represented in the RAS coIP mass spectrometric analysis from the different cell lines are provided in Table S5.

Immunoprecipitation and Western Blot Analysis
Routine methods to immunoprecipitate proteins were employed and detailed in the Supplemental Experimental Procedures. Antibodies used in the study are detailed in Table S3.

RAS-GTP Pull-Down Assay
The RAS-RAF interaction was studied using the RBD agarose beads as per manufacturer's instructions (Millipore) and detailed in the Supplemental Experimental Procedures.

Focus Formation Assay
Foci formation assays were performed by transfecting/co-transfecting (the indicated constructs) 150,000 early passage NIH 3T3 cells in 6-well dishes using Fugene HD (Promega). After 2 days, cells were trypsinized and plated onto 150 mm dishes containing 4%–5% calf serum. The cells were maintained under low serum conditions, and medium was refreshed every 2 days. After 21 days in culture, the plates were stained for foci using crystal violet.

Generation of NIH 3T3 *AGO2*−/− Line
AGO2-knockout NIH 3T3 cells were generated by CRISPR-Cas9-mediated genome engineering (Ran et al., 2013). Genomic regions in murine AGO2 between exons 8 and 9 and between exons 11and 12 were targeted for deletion using primers TCCTTGGTTACCCGATCCTGG and AGAGACTATCTG CAACTATGG, respectively (PAM motif underlined). Selection of clones is detailed in the Supplemental Experimental Procedures.

iSHiRLoC Analyses
Oligos (*let-7*-a1 guide: P-UGA GGU AGU AGG UUG UAU AGU U-X Cy5, where X = Cy3 or Cy5; *let-7*-a1-passenger: P-CUA UAC AAU CUA CUG UCU UUC C-Y, where Y = OH, Cy3, or Cy5) were microinjected in cells and incubated in phenol red-free DMEM containing 2% (v/v) CS in the presence of a 5% CO_2 atmosphere at 37°C for the indicated amounts of time prior to imaging. Details of microinjection and imaging are provided in the Supplemental Experimental Procedures.

Extract Preparation and In Vitro miRNA Unwinding Assay
Cell extracts were prepared as described (Kwak and Tomari, 2012; Rakotondrafara and Hentze, 2011), with minor modifications detailed in Supplemental Experimental Procedures.

Further details on other methods are provided in the Supplemental Experimental Procedures.

Xenograft Studies
All experimental procedures involving mice were approved by the University Committee on Use and Care of Animals at the University of Michigan and conform to their relevant regulatory standards and are detailed in the Supplemental Experimental Procedures.

SUPPLEMENTAL INFORMATION

Supplemental Information includes Supplemental Experimental Procedures, seven figures, and five tables and can be found with this article online at http://dx.doi.org/10.1016/j.celrep.2016.01.034.

AUTHOR CONTRIBUTIONS

S.S. performed RAS/AGO2 immunoprecipitation, in vitro binding, cellular fractionation, immunoblot analyses, RAS/AGO2 knockdown, and overexpression cell-biology-based experiments. S.S. jointly conceived the study with C.K.-S. and A.M.C. *let-7*-based assays were carried out by S.P.; immunofluorescence analyses by S.P. and R.M.; sucrose density fractionation by R.M.; cloning and construct generation by V.K.; NIH3T3 *AGO2*−/− cells using CRISPR/Cas9 by Y.H.; IP-mass spectrometric analysis by A.K.Y.; experimental assistance and replication of studies by H.G.; microRNA sequencing and analysis by X.C. and S.M.D.; recombinant protein preparation and purification by J.A.S.; KRAS reagents and advice on KRAS biology by Y.W., A.F., K.S., and G.B.; single molecule analysis by S.P. and N.G.W.; manuscript preparation by S.S., C.K.-S., and A.M.C.; and funding and overall supervision of the study by A.M.C.

ACKNOWLEDGMENTS

REFERENCES

Baines, A.T., Xu, D., and Der, C.J. (2011). Inhibition of Ras for cancer treatment: the search continues. Future Med. Chem. *3*, 1787–1808.

Balmain, A., and Pragnell, I.B. (1983). Mouse skin carcinomas induced in vivo by chemical carcinogens have a transforming Harvey-ras oncogene. Nature *303*, 72–74.

Barceló, C., Etchin, J., Mansour, M.R., Sanda, T., Ginesta, M.M., Sanchez-Arévalo Lobo, V.J., Real, F.X., Capellà, G., Estanyol, J.M., Jaumot, M., et al. (2014). Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells. Gastroenterology *147*, 882–892.e8.

Benhamed, M., Herbig, U., Ye, T., Dejean, A., and Bischof, O. (2012). Senescence is an endogenous trigger for microRNA-directed transcriptional gene silencing in human cells. Nat. Cell Biol. *14*, 266–275.

Bivona, T.G., Quatela, S.E., Bodemann, B.O., Ahearn, I.M., Soskis, M.J., Mor, A., Miura, J., Wiener, H.H., Wright, L., Saba, S.G., et al. (2006). PKC regulates a farnesyl-electrostatic switch on K-Ras that promotes its association with Bcl-XL on mitochondria and induces apoptosis. Mol. Cell *21*, 481–493.

Brenner, J.C., Ateeq, B., Li, Y., Yocum, A.K., Cao, Q., Asangani, I.A., Patel, S., Wang, X., Liang, H., Yu, J., et al. (2011). Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell *19*, 664–678.

Broderick, J.A., Salomon, W.E., Ryder, S.P., Aronin, N., and Zamore, P.D. (2011). Argonaute protein identity and pairing geometry determine cooperativity in mammalian RNA silencing. RNA *17*, 1858–1869.

Burns, M.C., Sun, Q., Daniels, R.N., Camper, D., Kennedy, J.P., Phan, J., Olejniczak, E.T., Lee, T., Waterson, A.G., Rossanese, O.W., and Fesik, S.W. (2014). Approach for targeting Ras with small molecules that activate SOS-mediated nucleotide exchange. Proc. Natl. Acad. Sci. USA *111*, 3401–3406.

Cao, Q., Wang, X., Zhao, M., Yang, R., Malik, R., Qiao, Y., Poliakov, A., Yocum, A.K., Li, Y., Chen, W., et al. (2014). The central role of EED in the orchestration of polycomb group complexes. Nat. Commun. *5*, 3127.

Cheng, C.M., Li, H., Gasman, S., Huang, J., Schiff, R., and Chang, E.C. (2011). Compartmentalized Ras proteins transform NIH 3T3 cells with different efficiencies. Mol. Cell. Biol. *31*, 983–997.

Cichowski, K., and Jacks, T. (2001). NF1 tumor suppressor gene function: narrowing the GAP. Cell *104*, 593–604.

COSMIC (2013). Catalog of Somatic Mutations in Cancer, COSMIC Release v66 (Wellcome Trust Sanger Institute).

Cox, A.D., and Der, C.J. (2010). Ras history: The saga continues. Small GTPases *1*, 2–27.

Czech, B., and Hannon, G.J. (2011). Small RNA sorting: matchmaking for Argonautes. Nat. Rev. Genet. *12*, 19–31.

DeFeo, D., Gonda, M.A., Young, H.A., Chang, E.H., Lowy, D.R., Scolnick, E.M., and Ellis, R.W. (1981). Analysis of two divergent rat genomic clones homologous to the transforming gene of Harvey murine sarcoma virus. Proc. Natl. Acad. Sci. USA *78*, 3328–3332.

Diederichs, S., and Haber, D.A. (2007). Dual role for argonautes in microRNA processing and posttranscriptional regulation of microRNA expression. Cell *131*, 1097–1108.

Downward, J. (2003). Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer *3*, 11–22.

Drosten, M., Dhawahir, A., Sum, E.Y., Urosevic, J., Lechuga, C.G., Esteban, L.M., Castellano, E., Guerra, C., Santos, E., and Barbacid, M. (2010). Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival. EMBO J. *29*, 1091–1104.

Dudley, N.R., and Goldstein, B. (2003). RNA interference: silencing in the cytoplasm and nucleus. Curr. Opin. Mol. Ther. *5*, 113–117.

Gagnon, K.T., Li, L., Chu, Y., Janowski, B.A., and Corey, D.R. (2014). RNAi factors are present and active in human cell nuclei. Cell Rep. *6*, 211–221.

Goldfinger, L.E., Ptak, C., Jeffery, E.D., Shabanowitz, J., Han, J., Haling, J.R., Sherman, N.E., Fox, J.W., Hunt, D.F., and Ginsberg, M.H. (2007). An experimentally derived database of candidate Ras-interacting proteins. J. Proteome Res. *6*, 1806–1811.

Gysin, S., Salt, M., Young, A., and McCormick, F. (2011). Therapeutic strategies for targeting ras proteins. Genes Cancer *2*, 359–372.

Hand, P.H., Thor, A., Wunderlich, D., Muraro, R., Caruso, A., and Schlom, J. (1984). Monoclonal antibodies of predefined specificity detect activated ras gene expression in human mammary and colon carcinomas. Proc. Natl. Acad. Sci. USA *81*, 5227–5231.

Höck, J., Weinmann, L., Ender, C., Rüdel, S., Kremmer, E., Raabe, M., Urlaub, H., and Meister, G. (2007). Proteomic and functional analysis of Argonaute-containing mRNA-protein complexes in human cells. EMBO Rep. *8*, 1052–1060.

Horman, S.R., Janas, M.M., Litterst, C., Wang, B., MacRae, I.J., Sever, M.J., Morrissey, D.V., Graves, P., Luo, B., Umesalma, S., et al. (2013). Akt-mediated phosphorylation of argonaute 2 downregulates cleavage and upregulates translational repression of MicroRNA targets. Mol. Cell *50*, 356–367.

Jeng, H.H., Taylor, L.J., and Bar-Sagi, D. (2012). Sos-mediated cross-activation of wild-type Ras by oncogenic Ras is essential for tumorigenesis. Nat. Commun. *3*, 1168.

Johnson, S.M., Grosshans, H., Shingara, J., Byrom, M., Jarvis, R., Cheng, A., Labourier, E., Reinert, K.L., Brown, D., and Slack, F.J. (2005). RAS is regulated by the let-7 microRNA family. Cell *120*, 635–647.

Karachaliou, N., Mayo, C., Costa, C., Magrí, I., Gimenez-Capitan, A., Molina-Vila, M.A., and Rosell, R. (2013). KRAS mutations in lung cancer. Clin. Lung Cancer *14*, 205–214.

Karnoub, A.E., and Weinberg, R.A. (2008). Ras oncogenes: split personalities. Nat. Rev. Mol. Cell Biol. *9*, 517–531.

Kim, Y.J., Maizel, A., and Chen, X. (2014). Traffic into silence: endomembranes and post-transcriptional RNA silencing. EMBO J. *33*, 968–980.

Kwak, P.B., and Tomari, Y. (2012). The N domain of Argonaute drives duplex unwinding during RISC assembly. Nat. Struct. Mol. Biol. *19*, 145–151.

Lampson, B.L., Pershing, N.L., Prinz, J.A., Lacsina, J.R., Marzluff, W.F., Nicchitta, C.V., MacAlpine, D.M., and Counter, C.M. (2013). Rare codons regulate KRas oncogenesis. Curr. Biol. *23*, 70–75.

Lauchle, J.O., Braun, B.S., Loh, M.L., and Shannon, K. (2006). Inherited predispositions and hyperactive Ras in myeloid leukemogenesis. Pediatr. Blood Cancer *46*, 579–585.

Lee, Y.S., and Dutta, A. (2007). The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev. *21*, 1025–1030.

Löhr, M., Klöppel, G., Maisonneuve, P., Lowenfels, A.B., and Lüttges, J. (2005). Frequency of K-ras mutations in pancreatic intraductal neoplasias associated with pancreatic ductal adenocarcinoma and chronic pancreatitis: a meta-analysis. Neoplasia *7*, 17–23.

Lu, J., Getz, G., Miska, E.A., Alvarez-Saavedra, E., Lamb, J., Peck, D., Sweet-Cordero, A., Ebert, B.L., Mak, R.H., Ferrando, A.A., et al. (2005). MicroRNA expression profiles classify human cancers. Nature *435*, 834–838.

MacRae, I.J., Ma, E., Zhou, M., Robinson, C.V., and Doudna, J.A. (2008). In vitro reconstitution of the human RISC-loading complex. Proc. Natl. Acad. Sci. USA *105*, 512–517.

Margarit, S.M., Sondermann, H., Hall, B.E., Nagar, B., Hoelz, A., Pirruccello, M., Bar-Sagi, D., and Kuriyan, J. (2003). Structural evidence for feedback

activation by Ras.GTP of the Ras-specific nucleotide exchange factor SOS. Cell 112, 685–695.

McCarthy, N. (2013). MicroRNA: lacking in maturity. Nat. Rev. Cancer 13, 377.

Meister, G., Landthaler, M., Peters, L., Chen, P.Y., Urlaub, H., Lührmann, R., and Tuschl, T. (2005). Identification of novel argonaute-associated proteins. Curr. Biol. 15, 2149–2155.

Ostrem, J.M., Peters, U., Sos, M.L., Wells, J.A., and Shokat, K.M. (2013). K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 503, 548–551.

Paroo, Z., Ye, X., Chen, S., and Liu, Q. (2009). Phosphorylation of the human microRNA-generating complex mediates MAPK/Erk signaling. Cell 139, 112–122.

Pershing, N.L., Lampson, B.L., Belsky, J.A., Kaltenbrun, E., MacAlpine, D.M., and Counter, C.M. (2015). Rare codons capacitate Kras-driven de novo tumorigenesis. J. Clin. Invest. 125, 222–233.

Peters, L., and Meister, G. (2007). Argonaute proteins: mediators of RNA silencing. Mol. Cell 26, 611–623.

Pitchiaya, S., Androsavich, J.R., and Walter, N.G. (2012). Intracellular single molecule microscopy reveals two kinetically distinct pathways for microRNA assembly. EMBO Rep. 13, 709–715.

Pitchiaya, S., Krishnan, V., Custer, T.C., and Walter, N.G. (2013). Dissecting non-coding RNA mechanisms in cellulo by Single-molecule High-Resolution Localization and Counting. Methods 63, 188–199.

Prior, I.A., and Hancock, J.F. (2012). Ras trafficking, localization and compartmentalized signalling. Semin. Cell Dev. Biol. 23, 145–153.

Pylayeva-Gupta, Y., Grabocka, E., and Bar-Sagi, D. (2011). RAS oncogenes: weaving a tumorigenic web. Nat. Rev. Cancer 11, 761–774.

Qiu, R.G., Chen, J., Kirn, D., McCormick, F., and Symons, M. (1995). An essential role for Rac in Ras transformation. Nature 374, 457–459.

Rakotondrafara, A.M., and Hentze, M.W. (2011). An efficient factor-depleted mammalian in vitro translation system. Nat. Protoc. 6, 563–571.

Ran, F.A., Hsu, P.D., Wright, J., Agarwala, V., Scott, D.A., and Zhang, F. (2013). Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 8, 2281–2308.

Rüdel, S., Flatley, A., Weinmann, L., Kremmer, E., and Meister, G. (2008). A multifunctional human Argonaute2-specific monoclonal antibody. RNA 14, 1244–1253.

Rüdel, S., Wang, Y., Lenobel, R., Körner, R., Hsiao, H.H., Urlaub, H., Patel, D., and Meister, G. (2011). Phosphorylation of human Argonaute proteins affects small RNA binding. Nucleic Acids Res. 39, 2330–2343.

Schubbert, S., Shannon, K., and Bollag, G. (2007). Hyperactive Ras in developmental disorders and cancer. Nat. Rev. Cancer 7, 295–308.

Shaw, R.J., and Cantley, L.C. (2006). Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441, 424–430.

Shen, J., Xia, W., Khotskaya, Y.B., Huo, L., Nakanishi, K., Lim, S.O., Du, Y., Wang, Y., Chang, W.C., Chen, C.H., et al. (2013). EGFR modulates microRNA maturation in response to hypoxia through phosphorylation of AGO2. Nature 497, 383–387.

Shieh, A., Ward, A.F., Donlan, K.L., Harding-Theobald, E.R., Xu, J., Mullighan, C.G., Zhang, C., Chen, S.C., Su, X., Downing, J.R., et al. (2013). Defective K-Ras oncoproteins overcome impaired effector activation to initiate leukemia in vivo. Blood 121, 4884–4893.

Shih, C., Padhy, L.C., Murray, M., and Weinberg, R.A. (1981). Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature 290, 261–264.

Spiegel, J., Cromm, P.M., Zimmermann, G., Grossmann, T.N., and Waldmann, H. (2014). Small-molecule modulation of Ras signaling. Nat. Chem. Biol. 10, 613–622.

Stalder, L., Heusermann, W., Sokol, L., Trojer, D., Wirz, J., Hean, J., Fritzsche, A., Aeschimann, F., Pfanzagl, V., Basselet, P., et al. (2013). The rough endoplasmic reticulum is a central nucleation site of siRNA-mediated RNA silencing. EMBO J. 32, 1115–1127.

Stephen, A.G., Esposito, D., Bagni, R.K., and McCormick, F. (2014). Dragging ras back in the ring. Cancer Cell 25, 272–281.

Sun, Q., Burke, J.P., Phan, J., Burns, M.C., Olejniczak, E.T., Waterson, A.G., Lee, T., Rossanese, O.W., and Fesik, S.W. (2012). Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated activation. Angew. Chem. Int. Ed. Engl. 51, 6140–6143.

Sweet, R.W., Yokoyama, S., Kamata, T., Feramisco, J.R., Rosenberg, M., and Gross, M. (1984). The product of ras is a GTPase and the T24 oncogenic mutant is deficient in this activity. Nature 311, 273–275.

Symonds, J.M., Ohm, A.M., Carter, C.J., Heasley, L.E., Boyle, T.A., Franklin, W.A., and Reyland, M.E. (2011). Protein kinase C δ is a downstream effector of oncogenic K-ras in lung tumors. Cancer Res. 71, 2087–2097.

Trahey, M., and McCormick, F. (1987). A cytoplasmic protein stimulates normal N-ras p21 GTPase, but does not affect oncogenic mutants. Science 238, 542–545.

Vasilescu, J., Guo, X., and Kast, J. (2004). Identification of protein-protein interactions using in vivo cross-linking and mass spectrometry. Proteomics 4, 3845–3854.

Wang, B., Li, S., Qi, H.H., Chowdhury, D., Shi, Y., and Novina, C.D. (2009). Distinct passenger strand and mRNA cleavage activities of human Argonaute proteins. Nat. Struct. Mol. Biol. 16, 1259–1266.

Wilson, R.C., and Doudna, J.A. (2013). Molecular mechanisms of RNA interference. Annu. Rev. Biophys. 42, 217–239.

Yang, M., Haase, A.D., Huang, F.K., Coulis, G., Rivera, K.D., Dickinson, B.C., Chang, C.J., Pappin, D.J., Neubert, T.A., Hannon, G.J., et al. (2014). Dephosphorylation of tyrosine 393 in argonaute 2 by protein tyrosine phosphatase 1B regulates gene silencing in oncogenic RAS-induced senescence. Mol. Cell 55, 782–790.

Zeng, Y., Sankala, H., Zhang, X., and Graves, P.R. (2008). Phosphorylation of Argonaute 2 at serine-387 facilitates its localization to processing bodies. Biochem. J. 413, 429–436.